Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

New England Journal of Medicine

Volumn 345, Issue 25, 2001, Pages 1809-1817

  Catella Lawson, Francesca ^a   Reilly, Muredach P ^a   Kapoor, Shiv C ^a   Cucchiara, Andrew J ^a   DeMarco, Susan ^a   Tournier, Barbara ^a   Vyas, Sachin N ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE B2;

ADULT; ANEMIA; ARTHRITIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; ENZYME ACTIVITY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-OVER STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DINOPROSTONE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IBUPROFEN; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; THROMBOXANE B2;

EID: 0035924765     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa003199     Document Type: Article

References (45)

1. Epidemiology of NSAID induced gastrointestinal complications
2. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high risk patients
3. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
4. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment
5. 2 as an amplifying signal for other agonists
6. Clinical pharmacology of platelet cyclooxygenase inhibition
7. Monitoring the entry of new platelets into the circulation after ingestion of aspirin
8. Evaluation of flurbiprofen for prevention of renifarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: The Flurbiprofen French Trial
9. Indobufen in the prevention of thromboembolic complications in patients with heart disease: A randomized, placebo-controlled, double-blind study
10. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
11. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing
12. COX-2 is not involved in thromboxane biosynthesis by activated human platelets
13. 2 synthase-1
14. 2 synthase
15. 2 synthase cyclooxygenase active site
16. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity
17. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin
18. Prospective evaluation of the utilization of aspirin and non-steroidal antiinflammatory drugs in acute medical admissions
19. The coxibs, selective inhibitors of cyclooxygenase-2
20. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
21. Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions
22. 2 production in human whole blood
23. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
24. Estimated rate of prostacyclin secretion into the circulation of normal man
25. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro
26. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
27. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
28. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
29. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding
30. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, doubleblind, placebo-controlled trial
31. Final report on the aspirin component of the ongoing Physicians' Health Study
32. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
33. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
34. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
35. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
36. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
37. Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase
38. Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2
39. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs
40. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers
41. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
42. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
43. Prostaglandins and the mode of action of antipyretic analgesic drugs
44. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee
45. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal antiinflammatory drugs